ASCO 2025, prostate cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), enzalutamide, 8-Year Outcomes of Enzalutamide Versus a Non-Steroidal Anti-Androgen, ENZAMET trial, ANZUP 1304 trial.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

I expected that becoming cancer-free would mean getting my old life back. Nothing could be further from the truth.

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...